Company Overview and News

Bank Negara moves to signal low interest rate days are over

AllianceDBS Research chief economist Manokaran Mottain said the hike will directly increase the base financing rate by as much as 25bps and deposit rates by as much as 20bps. “For the banking industry, the rate hike means higher margins from variable rate products,” he said in a report.

SC: Only 7of top 100 listed companies have all-male board members

The SC said in a statement that the seven remaining companies were Affin Holdings Bhd, Alliance Bank Bhd, Batu Kawan Bhd, Fraser & Neave Holdings Bhd, Genting Plantations Bhd, Genting Malaysia Bhd and UOA Development Bhd. Currently, the SC and the 30% Club Malaysia have been actively engaging the companies.

All-male board only in seven top firms, SC says as women power up in 2018

2018-01-21 themalaymailonline
A study by Khazanah Research Institute found that Malaysia ranked 106 out of 144 in the region in terms of women participating in the workforce. — Reuters picKUALA LUMPUR, Jan 21 — The lipstick squad is off to a great start this year with the Securities Commission (SC) announcing today that there are only seven public- listed companies in the top 100 nationwide that still have an all-male boardroom.

fAffin Bank raises stake in insurance arm or RM181mil

The proposed purchase price of RM180.54mil or RM11.78 a share cash will enable it to raise the shareholding from 37.07% to 49.95% comprising 59.46 million shares.

Affin Holdings Q3 net profit falls to RM73.3mil

Moving forward, Affin said its capital position is expected to be further strengthened by its corporate exercise to unlock more value for shareholders and provide better returns.

Breakfast briefing: Tuesday, October 3

MarketWatch: US stocks started the fourth quarter on a strong note on Monday, with all three major indexes hitting record high closes as data pointed to underlying strength in the economy. The DJIA rose 152.51 points, or 0.68%, to 22,557.6, the S&P 500 gained 9.76 points, or 0.39%, to 2,529.12 and the Nasdaq added 20.76 points, or 0.32%, to 6,516.72. - Reuters

Affin expects transfer listing to complete in first-half 2018

In its latest announcement on the reorganisation, AHB told Bursa Malaysia that it and Affin Bank had inked a share sale agreement (SSA) to transfer the entire shareholdings held by AHB in four companies to Affin Bank

Breakfast briefing: Tuesday, September 19

MarketWatch: The S&P 500 ended slightly higher on Monday as financial stocks rose ahead of a Federal Reserve meeting, but the Nasdaq pared gains sharply as technology stocks lost ground late in the session. The DJIA rose 63.01 points, or 0.28%, to 22,331.35, the S&P 500 gained 3.64 points, or 0.15%, to 2,503.87 and the Nasdaq added 6.17 points, or 0.1 percent, to 6,454.64. - Reuters

Affin gets BNM's nod to boost stake in AXA Affin General Insurance

Tags / Keywords: M&A , Insurance , Banking , Affin Holdings Bhd , AXA Affin General Insurance Bhd

Affin seeks to buy 7.07% in AXA Affin GI for RM99.09mil

Tags / Keywords: Corporate News , Banking , Affin Holdings Bhd , AXA Affin General Insurance Bhd

HLIB positive on Affin Holdings regulatory approvals

KUALA LUMPUR: Hong Leong Investment Bank Research (HLIB) is “positive” with the latest announcement by Affin Holdings Bhd that it has obtained regulatory approval to transfer listing to Affin Bank.

Affin gets go-ahead to pursue revamp plan

KUALA LUMPUR: Affin Holdings Bhd has received approvals from the Finance Minister and Bank Negara to proceed with the banking group’s proposed reorganisation.

Which banks are next?

WITH the ongoing merger talks between RHB Bank Bhd and AMMB Holdings Bhd, coupled with Bank Negara’s push for the institutionalisation of banks, the question of which banks will be the next merger and acquisitions (M&A) candidates has resurfaced.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

22h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

23h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...